BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22876620)

  • 1. 3D-QSAR studies of some tetrasubstituted pyrazoles as COX-II inhibitors.
    Gupta GK; Kumar A
    Acta Pol Pharm; 2012; 69(4):763-72. PubMed ID: 22876620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
    Dhanachandra Singh Kh; Karthikeyan M; Kirubakaran P; Nagamani S
    J Mol Graph Model; 2011 Sep; 30():186-97. PubMed ID: 21831680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore mapping studies on pyrazoles as anti-proliferative agents.
    Sharma V; Sharma V; Kumar P; Kumar V
    Pak J Pharm Sci; 2014 Nov; 27(6):1851-5. PubMed ID: 25362609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling, virtual screening and 3D-QSAR studies of 5-tetrahydroquinolinylidine aminoguanidine derivatives as sodium hydrogen exchanger inhibitors.
    Bhatt HG; Patel PK
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3758-65. PubMed ID: 22546667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
    Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
    J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CoMFA study of COX-2 inhibitors with receptor based alignment.
    Datar PA; Coutinho EC
    J Mol Graph Model; 2004 Dec; 23(3):239-51. PubMed ID: 15530820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
    Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
    J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
    Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
    J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
    Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
    Peng T; Pei J; Zhou J
    J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile.
    Sakya SM; Hou X; Minich ML; Rast B; Shavnya A; DeMello KM; Cheng H; Li J; Jaynes BH; Mann DW; Petras CF; Seibel SB; Haven ML
    Bioorg Med Chem Lett; 2007 Feb; 17(4):1067-72. PubMed ID: 17126015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, antitubercular evaluation and 3D-QSAR study of N-phenyl-3-(4-fluorophenyl)-4-substituted pyrazole derivatives.
    Khunt RC; Khedkar VM; Chawda RS; Chauhan NA; Parikh AR; Coutinho EC
    Bioorg Med Chem Lett; 2012 Jan; 22(1):666-78. PubMed ID: 22104148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of novel quinazolinone derivatives as inhibitors for 5HT7 receptor.
    Chitta A; Jatavath MB; Fatima S; Manga V
    J Recept Signal Transduct Res; 2012 Feb; 32(1):3-16. PubMed ID: 22171569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM; Ghoshal N
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors.
    Reddy KK; Singh SK; Dessalew N; Tripathi SK; Selvaraj C
    J Enzyme Inhib Med Chem; 2012 Jun; 27(3):339-47. PubMed ID: 21699459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.